Dräger yesterday announced it has received FDA clearance for its Seattle Positive Airway Pressure (PAP) plus system. Developed by Seattle Children’s Research Institute and produced and marketed by Dräger, the Seattle PAP plus leverages Bubble Continuous Positive Airway Pressure (CPAP) technology and further improves upon it to make it easier for premature infants with respiratory distress to breathe.
Worldwide, nearly 1 million infants die annually from respiratory distress syndrome (RDS). In the U.S. alone, there are approximately 18,000 hospitalizations each year due to RDS at a cost of approximately $2.3 billion.
Although Bubble CPAP has been a treatment option for neonates for more than 40 years, there has always been a desire to further reduce the work of breathing for these patients and increase the safety of the therapy. Historically, a major complication of Bubble CPAP in preemies is respiratory muscle exhaustion, where the baby’s respiratory muscles wear out, which can result in respiratory failure.1
The design of the Seattle PAP plus addresses both of these concerns. The 135-degree angle of the bubbler increases the oscillations with the goal of offering more efficient respiratory support, lessening the work required by respiratory muscles and making it easier for babies to breathe.1,  The second design difference is the locking mechanism for the pressure level, which avoids inadvertent changes of CPAP level and increases safety of the therapy delivered.
“Seattle Children’s Research Institute wanted a better option for treating respiratory distress in premature babies so we worked with them to bring a solution to the market that addresses a previously unmet need in the neonatal intensive care unit (NICU),” said Steve Menet, senior vice president of sales, hospital solutions, Draeger, Inc. “This is a great example of how healthcare industry stakeholders can come together to address a clinical need to improve patient outcomes.”
The Seattle PAP plus is effective, safe and easy to use:
- Efficacy: The patented design is totally focused on the infant’s clinical needs, enabling the clinician to:
- Easily adjust CPAP from 4.5 to 10 cm H2O
- Quickly connect the Seattle PAP plus system to the appropriate BabyFlow plus patient interface
- Treat patients with the needed masks and prongs in combination with BabyFlow plus
- Safety: The system incorporates safety features to avoid inadvertent changes in the position of the tube and subsequent changes in CPAP levels, which can cause serious harm to the infant. To eliminate the risk of cross-contamination, all system components are single-patient use.
- Ease of use: A single kit provides all the parts needed to assemble the Seattle PAP plus therapy, allowing the caregiver to worry less about assembly and more about the patient.
This new product further solidifies Dräger’s commitment to non-invasive and invasive ventilation from neonates to adults. For more information on Dräger’s complete portfolio of ventilation solutions, please visit our website.
Dräger. Technology for Life®
Dräger is an international leader in the fields of medical and safety technology. Our products protect, support and save lives. Founded in 1889, Dräger generated revenues of around EUR 2.6 billion in 2018. The Dräger Group is currently present in more than 190 countries and has more than 14,000 employees worldwide. Please visit www.draeger.com for more information.
Click here to directly request information about the Seattle CPAP plus System.
To learn more, visit us on Twitter @DraegerNews, LinkedIn, YouTube and Facebook.
 Short term evaluation of respiratory effort by premature infants supported with bubble nasal continuous airway pressure using Seattle-PAP and a standard bubble device. PLOS ONE, March 28, 2018, Stephen E. Welty et al.
 Respiratory Distress Syndrome of the Newborn, https://www.thoracic.org/patients/patient-resources/breathing-in-america/resources/chapter-19-respiratory-distress-syndr.pdf
 Bubble CPAP: is the noise important? An invitro study. Pediatr Res 2005;57(6):826-830. Pillow JJ, Travadi JN.
Be the first to comment